Charles A. Sanders, M.D., Partnership Award
In honor of its former Chairman of the Board, the FNIH celebrates its partners through the Charles A. Sanders, M.D., Partnership Award. In keeping with Dr. Sanders’ vision, the award recognizes persons and/or organizations that have made significant contributions to the FNIH’s work to build, implement and nurture private-public partnerships in support of the mission of the NIH.
The Partnership Award recipients are selected by a committee comprised of the following FNIH Board members:
- Charles A. Sanders, M.D.
- Steven M. Paul, M.D.
- Thomas R. Insel, M.D.
- Judy Lansing Kovler, Ph.D.
- Mr. Fred A. Seigel
- Solomon H. Snyder, M.D.
To donate, please contact firstname.lastname@example.org or visit here.
Please contact the Advancement Office for more information at email@example.com or 301-402-4976.
2022 Prize Recipients
During the 10th Annual 2022 FNIH Awards Ceremony, held on October 19, 2022, the Foundation for the National Institutes of Health presented its annual Charles A. Sanders, MD, Partnership Award to Dr. Francis Collins and Amgen, two partners who have supported and accelerated the work of the FNIH for many years. Dr. Collins will attend the Ceremony to receive his award. Robert A. Bradway, Amgen’s CEO, will attend to receive the award for Amgen.
2021 Prize Recipients
At the FNIH Awards Ceremony on October 20, the FNIH presented the 2021 Partnership Award to Janssen Research & Development, LLC, and to the eight Co-Chairs of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Groups.
Janssen Research & Development, LLC, has been an exemplary partner and leader across many FNIH projects and programs, including ACTIV; several Accelerating Medicines Partnerships®; the Biomarkers Consortium; the Partnership for Accelerating Cancer Therapies (PACT); and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Janssen members in their scientific leadership role have consistently promoted a highly collegial, collaborative approach to problem-solving with an emphasis on teamwork and transparent communication that enables open precompetitive science.
Mr. Alex Gorsky, Chairman, Board of Directors, and CEO of Johnson & Johnson, accepted the award for Janssen.
In support of finding therapeutics and vaccines to combat COVID-19, the Working Group Co-Chairs spent countless hours collaborating with the FNIH and NIH to design strategies for their areas and execute them with unprecedented speed. They participated in hundreds of meetings, reporting regularly to the ACTIV Leadership Team, and devoted valuable time and effort to identify opportunities for and help resolve challenges to the partnership. They have been invaluable to the ability of ACTIV to navigate the ever-changing scientific and political landscape during this all-encompassing global pandemic.
The Co-Chairs of the ACTIV Working Groups:
- Christine M. Colvis, Ph.D., Director of Drug Development Partnership Programs, National Center for Advancing Translational Sciences (NCATS) at NIH
- Elizabeth Desrosiers, M.S., P.M.P., Executive Director of Clinical Sciences and Study Management at Merck & Co., Inc
- Eric Hughes, M.D., Ph.D., Global Development Unit Head of Immunology, Hepatology and Dermatology, and China Region Development Head at Novartis
- Kathrin Jansen, Ph.D., Senior Vice President and Head of Vaccine Research and Development at Pfizer
- Michael Kurilla, M.D., Ph.D., Director, Division of Clinical Innovation, National Center for Advancing Translational Sciences (NCATS) at NIH
- Douglas Lowy, M.D., Principal Deputy Director, National Cancer Institute (NCI) at NIH
- Sarah Read, M.D., Deputy Director, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH
- John Young, Ph.D., Global Head of Infectious Diseases and Vice President at Roche
2020 Prize reciepent
The FNIH presented the 2020 Partnership Award to Dr. Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases. Dr. Fauci was honored for his legacy of leadership and ongoing support of FNIH programs propelling research in lethal infectious diseases, most recently for Covid-19.
In lieu of an in-person event to celebrate this achievement, the prize was presented via the online celebration of the 2020 FNIH awards.
2019 Prize Recipient
The FNIH presented The Doris Duke Charitable Foundation (DDCF) and Jane Sayer, Ph.D., as the recipients of the 2019 Charles A. Sanders, M.D., Partnership Award.
They were recognized for their longstanding support in advancing transformative NIH training and awards programs that empower future and current researchers, in addition to helping further the mission of the Foundation.
2018 Prize Recipient
The FNIH recognized Andrew Lee, President & CEO of Driven to Cure, Inc. as the recipient of the third Charles A. Sanders, M.D., Partnership Award.
Through his unwavering commitment to advancing biomedical research on rare kidney cancers, in just over two years, Andrew has developed a powerful grassroots movement that has increased visibility about rare kidney cancers and raised funds for the FNIH to further cutting-edge research conducted by the National Cancer Institute (NCI) at the NIH Clinical Center.
Read more in the FNIH press release.
2017 Prize Recipients
On October 18, 2017, the FNIH presented the 2nd Charles A. Sanders, M.D., Partnership Award to Richard J. Hodes, M.D., Director of the National Institute on Aging and Eli Lilly and Company (Lilly). Through their longstanding work with the FNIH over more than a decade, Dr. Hodes and Lilly have advanced trailblazing biomedical research in critical disease areas, including age-related disorders such as Alzheimer’s disease, and helped structure innovative public-private partnerships.
2016 Prize Recipients
On October 19, 2016, the FNIH presented the inaugural Charles A. Sanders, M.D., Partnership Award to two longstanding, private-sector partners:
- Bill & Melinda Gates Foundation: In recognition of its longstanding and generous partnership with the FNIH, which has spurred scientific and technical innovations leading to transformative advances in global health research.
- Pfizer: In recognition of its unwavering and sustained commitment for nearly two decades as a vital partner to the FNIH in funding scientific programs that have laid the groundwork for biomedical breakthroughs.